Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy.
5-Fluorouracil
Cisplatin
Cyclophosphamide
Gemcitabine
Immune checkpoint inhibitors
Irinotecan
Microbiota
Tyrosine kinase inhibitors
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
30
07
2019
revised:
05
09
2019
accepted:
08
09
2019
pubmed:
22
10
2019
medline:
21
1
2020
entrez:
22
10
2019
Statut:
ppublish
Résumé
Gut microbiota is involved in gastrointestinal carcinogenesis. Also, it modulates the activity, efficacy and toxicity of several chemotherapy agents, such as gemcitabine, cyclophosphamide, irinotecan, cisplatin and 5-Fluorouracil, and target therapy, such as tyrosine kinase inhibitors. More recently, accumulating data suggest that the composition of gut microbiota may also affect efficacy and toxicity of cancer immunotherapy. Therefore, the manipulation of gut microbiota through antibiotics, probiotics, prebiotics or fecal transplantation has been investigating with the aim to improve efficacy and mitigate toxicity of anticancer drugs.
Identifiants
pubmed: 31634731
pii: S1040-8428(19)30184-2
doi: 10.1016/j.critrevonc.2019.09.003
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
139-147Informations de copyright
Copyright © 2019. Published by Elsevier B.V.